Gilead signals ‘urgency’ for M&A, working ‘night and day’ on coronavirus response

To execute on its plan to launch 10 transformative medicines in 10 years, Gilead will make M&A a priority in bolstering its pipeline, CEO Daniel O’Day said on the company’s earnings call Tuesday. The company is also investing in manufacturing for its antiviral remdesivir in response to the 2019-nCoV outbreak.

Gilead Sciences Inc. (NASDAQ:GILD) will invest in external pipeline opportunities, including “transformative partnerships” like its deal with Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), as well as small- to medium-sized bolt-on acquisitions, O’Day said. ...